Toll-like receptor (TLR) 2 specific and antagonistic monoclonal antibody
TLR2 represents an “earliest possible” target for prevention and therapeutic
intervention in the pathogenesis of harmful immune reactions whose blockage abrogates entry of the initial inflammatory signal into first-line defense host cells.
Further Information: PDF
Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V.
Phone: +49 (0)89/1205-6000
Contact
Dr. Wolfgang Knappe
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Sea slugs inspire highly stretchable biomedical sensor
USC Viterbi School of Engineering researcher Hangbo Zhao presents findings on highly stretchable and customizable microneedles for application in fields including neuroscience, tissue engineering, and wearable bioelectronics. The revolution in…
Twisting and binding matter waves with photons in a cavity
Precisely measuring the energy states of individual atoms has been a historical challenge for physicists due to atomic recoil. When an atom interacts with a photon, the atom “recoils” in…
Nanotubes, nanoparticles, and antibodies detect tiny amounts of fentanyl
New sensor is six orders of magnitude more sensitive than the next best thing. A research team at Pitt led by Alexander Star, a chemistry professor in the Kenneth P. Dietrich…
